Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab-Reference-Cited by-同舟云学术

Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab

Published:2021-12 Issue: Volume: Page:
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Frances Nicolas,Bacac Marina,Bray-French Katharine,Christen François,Hinton Heather,Husar Elisabeth^ORCID,Quackenbush Elizabeth,Schäfer Martin,Schick Eginhard,Vyver Arthur Van De^ORCID,Richter Wolfgang F.^ORCID

Funder

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference32 articles.

1. Anti-CD20 antibody therapy for B-cell lymphomas;Maloney;N Engl J Med,2012

2. Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma and exposure-response in CLL;Gibiansky;CPT Pharmacometr Syst Pharmacol,2014

3. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma;Vitolo;J Clin Oncol,2017

4. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions;Goede;N Engl J Med,2014

5. Obinutuzumab for the first-line treatment of follicular lymphoma;Marcus;N Engl J Med,2017

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies;Pharmaceuticals;2024-08-09

2. Application of quantitative pharmacology analysis to support early clinical development of oncology drugs: dose selection;Xenobiotica;2024-08-08

3. Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas;2024-07-05

4. Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T‐Cell Engagers Development in Oncology;Clinical Pharmacology & Therapeutics;2024-07-04

5. Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC);Clinical Pharmacology & Therapeutics;2024-06-07